Time to rethink haemoglobin threshold guidelines in sickle cell disease

Alleviating anaemia in patients with sickle cell disease (SCD) is crucial in managing acute complications, mitigating end‐organ damage and preventing early mortality. Some disease‐modifying and curative therapies have increased haemoglobin (Hb) levels to exceed 100 g/l, a threshold above which compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballas, Samir K., Kuypers, Frans A., Gordeuk, Victor R., Hankins, Jane S., Thompson, Alexis A., Vichinsky, Elliott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Wider Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292304/
https://www.ncbi.nlm.nih.gov/pubmed/34131897
http://dx.doi.org/10.1111/bjh.17578
_version_ 1784749337961562112
author Ballas, Samir K.
Kuypers, Frans A.
Gordeuk, Victor R.
Hankins, Jane S.
Thompson, Alexis A.
Vichinsky, Elliott
author_facet Ballas, Samir K.
Kuypers, Frans A.
Gordeuk, Victor R.
Hankins, Jane S.
Thompson, Alexis A.
Vichinsky, Elliott
author_sort Ballas, Samir K.
collection PubMed
description Alleviating anaemia in patients with sickle cell disease (SCD) is crucial in managing acute complications, mitigating end‐organ damage and preventing early mortality. Some disease‐modifying and curative therapies have increased haemoglobin (Hb) levels to exceed 100 g/l, a threshold above which complications from red blood cell (RBC) transfusions have occurred, raising concern about whole‐blood viscosity‐related complications with these therapies. Here we discuss the rationale behind this limit, the effect of viscosity on blood flow and the applicability of this Hb threshold to therapies for SCD beyond RBC transfusions.
format Online
Article
Text
id pubmed-9292304
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92923042022-07-20 Time to rethink haemoglobin threshold guidelines in sickle cell disease Ballas, Samir K. Kuypers, Frans A. Gordeuk, Victor R. Hankins, Jane S. Thompson, Alexis A. Vichinsky, Elliott Br J Haematol Wider Perspectives Alleviating anaemia in patients with sickle cell disease (SCD) is crucial in managing acute complications, mitigating end‐organ damage and preventing early mortality. Some disease‐modifying and curative therapies have increased haemoglobin (Hb) levels to exceed 100 g/l, a threshold above which complications from red blood cell (RBC) transfusions have occurred, raising concern about whole‐blood viscosity‐related complications with these therapies. Here we discuss the rationale behind this limit, the effect of viscosity on blood flow and the applicability of this Hb threshold to therapies for SCD beyond RBC transfusions. John Wiley and Sons Inc. 2021-06-15 2021-11 /pmc/articles/PMC9292304/ /pubmed/34131897 http://dx.doi.org/10.1111/bjh.17578 Text en © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Wider Perspectives
Ballas, Samir K.
Kuypers, Frans A.
Gordeuk, Victor R.
Hankins, Jane S.
Thompson, Alexis A.
Vichinsky, Elliott
Time to rethink haemoglobin threshold guidelines in sickle cell disease
title Time to rethink haemoglobin threshold guidelines in sickle cell disease
title_full Time to rethink haemoglobin threshold guidelines in sickle cell disease
title_fullStr Time to rethink haemoglobin threshold guidelines in sickle cell disease
title_full_unstemmed Time to rethink haemoglobin threshold guidelines in sickle cell disease
title_short Time to rethink haemoglobin threshold guidelines in sickle cell disease
title_sort time to rethink haemoglobin threshold guidelines in sickle cell disease
topic Wider Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292304/
https://www.ncbi.nlm.nih.gov/pubmed/34131897
http://dx.doi.org/10.1111/bjh.17578
work_keys_str_mv AT ballassamirk timetorethinkhaemoglobinthresholdguidelinesinsicklecelldisease
AT kuypersfransa timetorethinkhaemoglobinthresholdguidelinesinsicklecelldisease
AT gordeukvictorr timetorethinkhaemoglobinthresholdguidelinesinsicklecelldisease
AT hankinsjanes timetorethinkhaemoglobinthresholdguidelinesinsicklecelldisease
AT thompsonalexisa timetorethinkhaemoglobinthresholdguidelinesinsicklecelldisease
AT vichinskyelliott timetorethinkhaemoglobinthresholdguidelinesinsicklecelldisease

Ejemplares similares